# Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects

> **NCT00498745** · PHASE1 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 36 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** neratinib

## Key facts

- **NCT ID:** NCT00498745
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 36 (—)
- **Last updated:** 2012-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498745, "Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00498745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*